TrialBMJ open2015

Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.

Vladimir Neychev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.